

LC-QTOF MS screening of more than 1000 licit and illicit drugs and their metabolites in wastewater and surface waters from the area of Bogotá, Colombia

Félix Hernández^{1*}, María Ibáñez¹, Ana-María Botero-Coy¹, Richard Bade¹, Martha Cristina Bustos-López², Javier Rincón³, Alejandro Moncayo³, Lubertus Bijlsma¹

¹*Research Institute for Pesticides and Water, University Jaume I, Castellón, Spain.*

²*Dep Ingeniería Civil y Agrícola, Universidad Nacional de Colombia, Bogotá, Colombia*

³*Dep Química, Facultad de Ciencias, Universidad Antonio Nariño, Bogotá, Colombia*

* Corresponding author: felix.hernandez@uji.es Tel.: +34 964 387366 Fax: +34 964 387368

Abstract

A large screening of around 1000 emerging contaminants, focused on licit and illicit drugs and their metabolites, has been made in urban wastewaters (both influent and effluent) and surface waters from the area of Bogotá, Colombia. After a simple generic solid-phase extraction (SPE) step with Oasis HLB cartridges, analyses were made by ultra high-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UHPLC-QTOF MS) under MS^E mode (sequential acquisition of mass spectra at low energy (LE) and high collision energy (HE)). Accurate-mass measurements and the information provided by MS^E on the presence of the (de)protonated molecule and fragment ions allowed the reliable identification of the compounds detected, even without reference standards being available in some cases (tentative identification). The compounds most frequently found were acetaminophen/paracetamol, carbamazepine and its dihydro-dihydroxylated metabolite, clarithromycin, diclofenac, ibuprofen, gemfibrozil, lincomycin, losartan, valsartan, the two metabolites of metamizole (4-acetamido-antipyrine and 4-formylamino-antipyrine), sucralose, and cocaine and its main metabolite benzoylecgonine. Caffeine, the sweetener saccharin and two hydroxylated metabolites of losartan were tentatively identified in almost all samples analysed. Pharmaceutical lidocaine was tentatively identified and subsequently confirmed with reference standard. For the first time, a general overview of the occurrence of drugs and their metabolites in the aquatic environment of Colombia has been reported. In the near future, target methodologies, typically based on LC-MS/MS, will need to be set up for accurate and sensitive quantification of the contaminants selected on the basis on the information provided in the present paper.

Keywords

Screening, ultra high-performance liquid chromatography, time-of-flight mass spectrometry, drugs, water, Colombia

Introduction

Changes in industry, agriculture and urban development present interlinked challenges to water quality [1, 2]. Due to the increasing use of pharmaceuticals and personal-care products (PCPs) as well as veterinary drugs and illicit drugs, the amount of these newly emerging chemicals detected in waters raise environmental and health concerns. Many of these contaminants survive the passage through conventional wastewater treatment processes resulting in the growing discharge of these compounds into receiving waters where their presence is increasingly common [3, 4]. However, little information is available from Latin America despite the fact that this region undergoes rapid land, economical, and social changes [5] and where, in some areas, the discharge of raw sewage into rivers, lakes and reservoirs are widely practiced [6 - 8]. Concern over the presence of these contaminants is well founded as these rivers not only flow through tropical areas rich in biodiversity, but surface waters are also used as a source for human consumption after conventional chlorination processes or directly as irrigation water without any treatment.

Monitoring licit and illicit drugs is generally based on multi-residue methodologies using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) for target substances considered as harmful for human health or the ecosystem. Analyses are commonly focused on a limited number of priority compounds, and the main objective is the accurate quantification of the target analytes. However, the use of pharmaceuticals and veterinary drugs differs temporally and spatially between regions and countries due to different marketing, regulations, prescription practices, etc. [9]. Thus, drugs used in Latin America may differ from those generally prescribed or consumed in Europe and North America. Accordingly, target approaches applied for routine analysis of water samples in one country might ignore important contaminants from another country, as they are simply not included in the scope of the method. Therefore, a large screening of contaminants is of high interest in order to define priority compounds and to subsequently set up target methodologies for monitoring. To this end, High Resolution Mass Spectrometry (HRMS) plays an important role for screening of emerging contaminants, in relevant fields like environmental pollution [10, 11].

Hybrid HRMS, such as a quadrupole time-of-flight mass spectrometry (QTOF MS) in MS^E or all ions MS/MS mode (the term depends on the manufacturer), has

demonstrated its use as an advanced tool that allows the investigation of hundreds of compounds in the same run, making use of home-made databases [12 - 14]. The presence of compounds in samples can be investigated once the analysis has been performed and data acquired, without being dependent on the pre-selection of analytes. It allows detection/rapid screening for compounds by means of searching the exact mass of the (de)protonated molecules in the full spectra generated using low collision energy (LE function). Confirmation with reference standards, or tentative identification, could subsequently be performed searching for exact masses of fragment ions in the acquired spectra at high collision energy (HE), where fragmentation of the molecule is promoted.

We performed a previous monitoring in the irrigate district of Usosaldaña, an important agricultural area in Colombia, mainly devoted to the cultivation of rice. Analysis of surface water and soil samples by TOF MS, coupled to both gas and liquid chromatography, revealed the presence of several pesticides and metabolites in most of the samples. Also, some personal care products were identified [15]. However, there is little or no information on the presence of emerging organic contaminants in the area of Bogotá. In the present work, a large screening of pharmaceuticals belonging to different therapeutic groups, veterinary drugs, X-ray agents, PCPs (preservatives and UV filters), sweeteners, illicit drugs and a notable number of metabolites has been performed in urban wastewaters (both influent and effluent) and receiving surface waters from the surrounding area of Bogotá. A customized database with more than 1000 emerging contaminants was developed including pharmaceuticals frequently prescribed in Colombia. As far as we know, this is the first wide-scope screening based on HRMS that has been applied to this aim. Henceforth, future monitoring in this area can be focused on the compounds identified in this initial step.

Material and Methods

Chemicals and standards

865 human and veterinary pharmaceuticals including metabolites (see Supplementary information (SI), **Table SI1**), 29 X-Ray agents (**Table SI2**), 20 UV-filters (**Table SI3**), 4 preservatives (**Table SI4**), 9 sweeteners (**Table SI5**) and 130 illicit drugs including metabolites (**Table SI6**) were studied, of which 215 reference standards were available (* in **Tables SI1 – SI6**).

Reference standards of these compounds were purchased from Across Organics (Geel, Belgium), Aventis Pharma (Madrid, Spain), Bayer Hispania (Barcelona, Spain), Cerilliant (Round Rock, TX, USA), Fluka (Buchs, Switzerland), Dr. Ehrenstorfer (Augsburg, Germany), Fort Dodge Veterinaria (Gerona, Spain), LGC Promochem (London, UK), National Measurement Institute (Pymble, Australia), Riedel-de Haën (Seelze, Germany), Sigma Aldrich (St Louis, MO, USA), Toronto Research Chemicals (Ontario, Canada), Vetoquinol Industrial (Madrid, Spain), and Witega (Berlin, Germany). All reference materials had purities higher than 98% (w/w), except for marbofloxacin and pefloxacin, which had purities higher than 93%.

HPLC-grade methanol (MeOH), HPLC-grade acetonitrile (ACN), sodium hydroxide (NaOH) (>99% w/w) and formic acid (HCOOH) (>98 % w/w) were purchased from Scharlau (Barcelona, Spain). Leucine enkephalin was purchased from Sigma Aldrich (Madrid, Spain). HPLC-grade water was obtained by purifying demineralised water in a Milli-Q plus system from Millipore (Bedford, MA, USA). Solid-phase extraction (SPE) cartridges used were Oasis HLB 3 cm³ (60 mg) from Waters (Milford, MA, USA).

Samples

Seven influent wastewater (IWW) samples and seven effluent wastewater (EWW) samples were taken from the Salitre wastewater treatment plant (WWTP), in Northwest Bogotá D.C., Colombia, which serves a population of approximately three million inhabitants. The 24-hour composite samples were collected over seven consecutive days in March 2014 (starting on Wednesday March 12th and ending on Tuesday March 18th) in high density polystyrene bottles, immediately centrifuged and stored in the dark at -20°C until analysis. In addition, ten grab surface water (SW) samples were collected from around Bogota (**Figure 1**) in July 2013, concerning areas of interest along the

Tunjuelo River (samples 1-4) and in La Ramada Irrigation District (samples 5-10). Seven individual samples (250 mL) were taken for each sampling point. These were then combined to form a composite sample to provide a more complete overview of each area. An aliquot was then taken for the sample treatment and subsequent analysis.

Sample Treatment

An SPE step was applied prior to analysis to pre-concentrate the sample. All samples were filtered through 0.45 μm mixed cellulose ester membrane filter (Whatman, Dassel, Germany). SPE was performed using Oasis HLB cartridges (60 mg). The cartridges were conditioned by washing and rinsing with 6 mL MeOH and 6 mL Milli-Q water. The water samples (IWW was four times diluted with MilliQ water, i.e. 25 mL sample in 100 mL; EWW and SW was 100 mL, no dilution) were loaded onto the cartridges, percolated by gravity (flow rate around 3 mL/min) and vacuum dried for approximately 15 min. Analytes were eluted with 5 mL MeOH. The extracts were evaporated to dryness at 35°C under a gentle stream of nitrogen and reconstructed in 1 mL of 10:90 MeOH:H₂O. Analyses were performed by injecting 20 μL of the final extract into the UHPLC-QTOF-MS

Instrumentation

A Waters Acquity UPLC system (Waters, Milford, MA, USA) was interfaced to a hybrid quadrupole-orthogonal acceleration-TOF mass spectrometer (XEVO G2 QTOF, Waters Micromass, Manchester, UK), using a Z-Spray ESI interface operating in both positive and negative ion mode. The chromatographic separation was performed using an Acquity UPLC BEH C18 1.7 μm particle size column 100 \times 2.1 mm (Waters) at a flow rate of 300 $\mu\text{L}/\text{min}$. The mobile phases used were A = H₂O with 0.01% HCOOH and B = MeOH with 0.01% HCOOH. The initial percentage of B was 10%, which was linearly increased to 90% in 14 min, followed by a 2 min isocratic period and, then, returned to initial conditions during 2 min. The total run time was 18 minutes. Nitrogen was used as drying gas and nebulizing gas. The desolvation gas flow was set at 1000 L/h and the cone gas at 80 L/h. TOF-MS resolution was approximately 20,000 at full width half maximum (FWHM) at m/z 556.

MS data were acquired in centroid mode over an m/z range of 50–1000 Da. Data were acquired in both positive and negative ionization modes in two separate runs. A capillary voltage of 0.7 kV and 2.5 kV were used in positive and negative ionizations modes, respectively. A cone voltage of 20 V was used. Collision gas was argon 99.995% (Praxair, Valencia, Spain). The desolvation temperature was set to 600°C, and the source temperature to 130 °C. The column temperature was set to 40°C.

For MS^E experiments, two acquisition functions with different collision energies were created. The low energy (LE) function, selecting a collision energy of 4 eV, and the high energy (HE) function, with a collision energy ramp ranging from 15-40 eV in order to obtain a greater range of fragment ions. The LE and HE functions settings were for both a scan time of 0.4 s.

For elucidation of losartan metabolites, MS/MS experiments at different collision energies (10, 20, 30, 40 and 50 eV) were performed to promote higher fragmentation and also to ensure that fragment ions observed in MS^E come from the parent ion.

Data Processing

Processing of MS data was done using ChromaLynx XS application manager (within MassLynx v 4.1; Waters Corporation). The following parameters were used for screening: mass window 150 ppm (for positive ID \leq 5 ppm), isotope fit as well as retention time (maximum deviation of \leq 2.5%) and fragmentation, when available. Software specific settings were: peak width at 5% height: 6 seconds, peak-to-peak baseline noise: 1000 and threshold absolute area: 200.

Results and discussion

Detection, confirmation and tentative identification

The full-spectrum accurate-mass data, generated by QTOF under MS^E mode, were inspected in ChromaLynx XS (within MassLynx) using a home-made database containing 1057 LC-amenable organic contaminants (**Tables SI1 – SI6**), which is continuously being updated. Analytes were mostly selected based on our own experience and on existing compound lists encountered in the literature on LC–MS methods for determination of organic contaminants. Empirical data (retention time, adduct information and/or fragment ions) obtained from compounds of which reference standards (up to 215) were available in our laboratory was included. This information was used for an easier and more straightforward detection and unambiguous confirmation of the identity of the compound. Furthermore, pharmaceuticals frequently prescribed in Colombia were also included. For those compounds for which reference standards were not available at our laboratory, the only information included in the database was the name and elemental composition of the compounds. Here, the tentative identification was a manual and more time-consuming process, incorporating internet resources, such as MassBank [16] or MetLin [17] to look for information about possible fragment ions.

The confidence in HRMS based identification is an important issue as pointed out by Schymanski *et al.* [18]. Discussion on how to best communicate confidence regarding identification for the exchange of results via literature and databases is on-going, but criteria are needed and should be well reported. Criteria used in this study were based on the availability (detection and confirmation of the identity) or non-availability (tentative identification) of reference standards. The information given by QTOF MS spectra, both LE and HE accurate mass spectra, and retention times allowed the compounds to be distinguished using different possibilities:

- *Detection*, based on the presence of 1 accurate-mass ion (mass error ≤ 5 ppm) and retention time agreement (maximum deviation $\leq 2.5\%$)
- *Confirmation of the identity*, with at least 2 accurate-mass ions (≤ 5 ppm) and retention time ($\leq 2.5\%$)
- *Tentative identification*, with at least 2 accurate-mass ions justified by literature data and /or compatibility with candidate chemical structure

For those compounds containing chlorine or bromine atoms, the characteristic isotopic profile should be observed. However, we considered the isotopic pattern as a prerequisite for identification, but not as valuable as an accurate-mass fragment ion. Therefore, when only those ions corresponding to the parent compound and the isotopic peak were present, we considered the compound as detected, not as confirmed.

In the case of tentative identification, reference standards and additional MS/MS experiments would be necessary for final unequivocal confirmation of the compounds. However, we do not need expensive reference standards for all 1057 compounds in the database, only for the positive findings. From our previous experience, the subsequent acquisition of reference standards has allowed confirmation of nearly all tentative identifications. This supports the high degree of reliability of tentative identification by using this technique [19].

Screening of Colombian water samples

In order to perform a large screening, a non-selective sample treatment and a generic chromatographic separation was chosen to broaden the system applicability to as many compounds as possible. Due to the large level of dilution in these types of samples, SPE was performed, using a generic Oasis HLB cartridge for pre-concentration and to enable detecting the analytes at the low concentration levels normally present. Using this analytical procedure and from the information obtained by UHPLC-QTOF MS under MS^E mode, several compounds could be detected, confirmed and/or tentatively identified in all type of Colombian water samples analyzed (**Table 1**).

Samples were screened for pharmaceuticals belonging to different therapeutic groups, veterinary drugs, X-ray agents, PCPs (preservatives and UV filters), sweeteners, illicit drugs and several metabolites. The compounds most frequently detected were the analgesics/anti-inflammatories N-acetyl-p-aminophenol (commonly known as acetaminophen or paracetamol), diclofenac, ibuprofen and lidocaine. The antibiotics clarithromycin and lincomycin, the angiotensin II antagonists valsartan and losartan, the anti-epileptic carbamazepine, the beta-blocker metoprolol, the lipid regulator gemfibrozil and the X-ray agent iopromide were also found. It is interesting to remark the detection or tentative identification of several metabolites such as those of

metamizole (4-acetylamino-antipyrine and 4-formylamino-antipyrine), carbamazepine-10,11-dihydro-10, 11-dihydroxy and three metabolites of losartan (losartan carboxylic acid, and two hydroxy-losartan isomers). Furthermore, the sweeteners acesulfame, sucralose and saccharin and the psychoactive drugs, cocaine and its main metabolite benzoylecgonine, as well as caffeine were frequently detected or tentatively identified. UV-filters were not detected, while the preservatives methylparaben and propylparaben were found, but only in wastewater samples.

These data are consistent with studies on over the counter medicines in Colombia, where analgesics are most frequently sold (60%), in Bogotá [20]. In addition, 11% of the population of Bogotá has been diagnosed with hypertension of which 5.5% taking mainly losartan, valsartan and metoprolol for its control [21] and regarding antibiotics, clarithromycin and lincomycin are most often prescribed [22].

Based on general population surveys, cocaine is the second most consumed illicit drug, but the main illicit psychoactive drug consumed in Colombia is cannabis [23]. However, the main metabolite of cannabis (11-nor-9-carboxy- Δ^9 -tetrahydrocannabinol (THC-COOH)), which is commonly used as biomarker in wastewater for cannabis consumption, was not detected. This was probably due to the low sensitivity of the technique applied for this compound. The analytical problems found in the determination of this compound have been widely recognized in the literature [24 - 26].

Most compounds were found in both wastewaters (influent and effluent) and surface waters suggesting incomplete removal by WWTPs and possible disposal to receiving surface waters. The pharmaceuticals carbamazepine and its metabolite carbamazepine-10, 11-dihydro-10, 11 dihydroxy, acetaminophen, diclofenac, ibuprofen, the highly consumed caffeine, cocaine and its metabolite benzoylecgonine are widely occurring contaminants in the aquatic environment, having been reported to be also present in Brazilian surface waters [5, 7].

In relation to surface waters, the presence of pharmaceuticals was more noticeable in samples collected from the Tunjuelo river (samples 1 to 4) -a tributary of the Bogotá river- in the south of Bogotá. In this area, around 2.5 million inhabitants discharge their sewage directly to this river without any treatment. In addition, solid urban waste are located here (Doña Juana landfill, **Figure 1**) and potential leaching surely contributes to the pollution in the area. This can explain that the profile of emerging contaminants found in these surface waters and in wastewaters collected from Salitre WWTP was

rather similar, in both cases reflecting the drug consumption of a large population (2.5 - 3 million inhabitants).

In contrast, the irrigation area of Ramada -supplied by the Bogotá river in its northern part- may be affected by industrial and urban waste, albeit with a lower population (around 600.000 inhabitants). Although these surface water samples (5 to 10) had several contaminants in common with those samples from the Tunjuelo river and with wastewater samples, the number of compounds detected was notably lower. Despite this fact, the presence of emerging contaminants may have undesirable consequences for public health as these waters are mainly used for irrigation on this agricultural area. A more in-depth study would be required to quantify the compounds detected in water samples from this area for better knowledge and estimation of potential human risks.

Below, some examples are given in detail, to illustrate the screening strategy applied in this study, which led to the detection, confirmation or tentative identification of several compounds. The different possibilities considered in this work will be taken into account: presence/absence of reference standards in the laboratory, and searching for known and unknown metabolites on the basis of common fragmentation pathway between parent compound and possible metabolites.

a) Reference standards available

Up to 215 reference standards were available in our laboratory and, therefore, experimental data such as retention time and fragment ions could be included in the home-made database. This information was used for easier detection and unambiguous confirmation of the identity of the compounds. **Figure 2** shows the unequivocal confirmation in surface water of 4-acetamido antipyrine, a metabolite of the widely used analgesic metamizole. The LE spectrum (Figure 2a, top) of the peak at 3.78 min showed the m/z corresponding to the protonated molecule (m/z 246.1237) with a mass error of -2.4 ppm. The HE spectrum (Figure 2a, bottom) also showed the remaining protonated molecule and five fragment ions with mass errors all below 5 ppm. In this figure, narrow-window eXtracted Ion Chromatograms (nw-XICs) for the six m/z ions are also depicted, with a chromatographic peak at exactly the same retention time.

In a similar way, most of the detected compounds could be confirmed in the samples (see the compounds marked as \checkmark in **Table 1**). The compounds metoprolol and codeine

could not be confirmed despite the reference standards were available, as only the protonated molecule was observed at the corresponding retention time. In these cases the compounds were marked as detected (• in **Table 1**). Additional analysis would be required to promote the fragmentation, using higher collision energies in new MS/MS experiments.

b) Reference standards not available

When reference standards were unavailable, the only information included in the database was the name and elemental composition of the contaminants. Even in this situation, a tentative identification could be performed on the basis of the relevant information on the accurate mass of the (de)protonated molecule and the fragment ions offered by QTOF MS^E. **Figure 3** illustrates the potential of this screening approach with two case studies: the detection and tentative identification of lidocaine and caffeine in effluent wastewater.

The LE spectrum in ESI positive of an abundant chromatographic peak at 3.97 min, showed an intense signal at m/z 235.1808 (**Figure 3a, bottom**). This might correspond to the protonated molecule of lidocaine (C₁₄H₂₃N₂O, expressed as protonated molecule), with a mass error of -0.9 ppm in relation with the theoretical exact mass. The LE spectrum also showed an important signal at m/z 195.0883 (retention time 3.89 min) which could be attributed to caffeine (C₈H₁₁N₄O₂, 0.5 ppm mass error). The HE spectrum showed 3 fragment ions at m/z 138.0667 (C₆H₈N₃O), 110.0716 (C₅H₈N₃) and 86.0971 (C₅H₁₂N), all with mass errors below 2 ppm (**Figure 3a, top**). At this point, UHPLC was a valuable tool for selecting almost co-eluting fragment ions that might correspond to different precursor ions. Thus, the fragments at m/z 138 and 110 were related to caffeine, whereas the fragment at m/z 86 was related to lidocaine. The structure of the fragment ions were justified on the basis of their measured accurate masses, which was moreover in agreement with the information available in scientific literature [16, 17]. Lidocaine could be tentatively identified and subsequently confirmed after acquiring its reference standard (⊕√ in **Table 1**). The confirmation of caffeine would require the injection of the reference standard, which at the time of writing this paper was not available at our laboratory (we did not consider this compound relevant in our study). Similar situations occurred for other compounds tentatively identified, as

metformin, pirantel and the sweetener saccharin, due to the lack of reference standard (\oplus in **Table 1**).

c) Searching for metabolites

A detailed discussion is made on the particular case of losartan, an angiotensin II receptor antagonist drug used mainly to treat high blood pressure (hypertension), and its metabolites identified making use of the common fragmentation pathway.

Losartan was confirmed to be present in all the samples analyzed. The LE spectrum in ESI+ showed an abundant chromatographic peak at the expected retention time (10.13 min) for this pharmaceutical (m/z 423.1695, -1.2 ppm mass error) and also presented the typical isotopic pattern of a chlorine atom ($C_{22}H_{24}N_6OCl$, expressed as protonated molecule). The expected fragment ion at m/z 405.1590 ($C_{22}H_{22}N_6Cl$, -1.0 ppm), due to a loss of water, was also observed in the LE spectrum, as well as a minor fragment ion at m/z 377.1528 ($C_{22}H_{22}N_4Cl$, -1.3 ppm), corresponding to a N_2 loss from m/z 405. The HE spectrum showed a predominant ion at m/z 207.0916 ($C_{14}H_{11}N_2$), and minor peaks at m/z 235.0979 ($C_{14}H_{11}N_4$), 192.0813 ($C_{14}H_{10}N$), 190.0661 ($C_{14}H_8N$) and 180.0805 ($C_{13}H_{10}N$), all with mass errors below 4 ppm. These fragments correspond to the fragmentation at the benzylic carbon (CH_2 near to the two rings) (m/z 235) with losses of N_2 (m/z 207), N_3H (m/z 192) or N_3H_3 (m/z 190). Losartan was also detected in negative mode at m/z 421.1552, showing fragment ions at m/z 187.0631 ($C_8H_{12}N_2OCl$), 179.0868 ($C_{14}H_{11}$), 157.0529 ($C_7H_{10}N_2Cl$) and 127.0066 ($C_5H_4N_2Cl$). With all this information, the compound detected in the samples was unequivocally confirmed to be losartan.

The presence of three additional chromatographic peaks at 8.25, 9.29 and 10.47 min in all the three XICs at m/z 207, 235 and 190 performed at the HE function in ESI+ (for losartan, retention time 10.13 min) suggested that the three compounds were chemically related with this pharmaceutical (**Figure 4**). The common fragmentation pathway strategy has been successfully applied by our group in the elucidation of metabolites of the new psychoactive substance methylenedioxypropylvalerone (MDPV) and of degradation products of cocaine and benzoylecgonine [27, 28]. This encouraged us to investigate the identity of the potential metabolites/transformation products of losartan from the data provided by QTOF MS.

Firstly, the LE spectra (all showing the isotopic distribution corresponding to a chlorine atom) of these 3 possible metabolites were studied in more detail. In relation to the peak at 10.47 min, the protonated molecule corresponded to m/z 437.1490 ($C_{22}H_{22}N_6O_2Cl$, -0.7 ppm), which might be attributed to an oxidation of losartan. This compound might correspond to losartan carboxylic acid, the main metabolite reported in the literature [29].

Regarding the peaks at 8.25 and 9.29 min, accurate masses of m/z 439.1643 and 439.1661 were obtained, respectively, both corresponding to the same empirical formulae $C_{22}H_{24}N_6O_2Cl$ with mass errors lower than 3 ppm. This implies the presence of an extra oxygen atom with respect to losartan. Hence, these two compounds might correspond to hydroxylated metabolites of losartan.

The following step consisted on the elucidation of the structure of these three potential metabolites. For this purpose, MS/MS experiments were performed at different collision energies (10-50 eV).

Regarding the peak at 10.47 min (m/z 437.1490, $C_{22}H_{22}N_6O_2Cl$, -0.7 ppm), 5 common product ions with losartan were observed at m/z 235.0982, 207.0919, 192.0816, 190.0654 and 180.0809. This compound was also detected in negative mode, with m/z 435.1327 ($C_{22}H_{22}N_6O_2Cl$, -2.1 ppm). At the lowest collision energy, a product ion was observed at m/z 391.1429 ($C_{21}H_{20}N_6Cl$, -2.3 ppm), corresponding to a loss of CO_2 . When the collision energy was increased, product ions at m/z 363.1375 ($C_{21}H_{20}N_4Cl$, this is a N_2 loss from 391, -0.3 ppm), 157.0530 ($C_7H_{10}N_2Cl$, -1.9 ppm) and 113.9989 ($C_4H_3N_2Cl$, 3.5 ppm) were observed. All these fragments fitted with the chemical structure of losartan carboxylic acid. After this careful evaluation and well-supported tentative identification, the reference standard of losartan carboxylic acid was acquired and injected, allowing the ultimate confirmation of this metabolite in the samples.

Regarding the hydroxylated metabolite 1 (8.25 min, m/z 439.1643, $C_{22}H_{24}N_6O_2Cl$, -1.4 ppm), two minor product ions were observed at 10 eV at m/z 421.1536 ($C_{22}H_{22}N_6OCl$) and 385.1772 ($C_{22}H_{21}N_6O$), resulting from a loss of water and subsequent loss of hydrochloric acid. At higher collision energies, product ions at m/z 235.0978 ($C_{14}H_{11}N_4$), 207.0915 ($C_{14}H_{11}N_2$), 192.0806 ($C_{14}H_{10}N$), 190.0649 ($C_{14}H_8N$) and 180.0803 ($C_{13}H_{10}N$) were obtained (**Figure 5a**). Thus, ESI+ fragmentation advise about what is happening near to the tetrazol group but not about the location of the hydroxyl group. Accordingly, these fragments seem to indicate that the hydroxylation has

occurred in the imidazole part. In negative mode, product ions at m/z 203.0585 ($C_8H_{12}N_2O_2Cl$) and 173.0488 ($C_7H_{10}N_2OCl$) were observed at 20 eV. When the collision energy was increased up to 50 eV, product ions at m/z 155.0384 ($C_7H_8N_2Cl$), 127.0060 ($C_5H_4N_2Cl$), 113.9991 ($C_4H_3N_2Cl$) and 100.9912 ($C_3H_2N_2Cl$) were observed (**Figure 5b**). Considering all this information, the $-OH$ group could be placed in the benzimidazole part, being an N-oxide the most plausible candidate. Otherwise, if the hydroxyl group was located in the alkylic chain, a second loss of water should in principle be observed in ESI+.

Regarding the hydroxylated metabolite 2 (9.29 min, m/z 439.1645, $C_{22}H_{24}N_6O_2Cl$, -0.9 ppm), two important fragment ions were observed at 10 eV (ESI+) at m/z 421.1538 ($C_{22}H_{22}N_6OCl$) and 403.1435 ($C_{22}H_{20}N_6Cl$) corresponding to two consecutive losses of water. At higher collision energies, the common fragment ions at m/z 235.0983, 207.0920, 192.0811, 190.0659 and 180.0808 were observed. The spectra in negative mode was different from that of losartan and the other hydroxylated metabolite (e.g. respectively m/z 187/157 or 203/173 were not seen) and only two product ions at m/z 100.9908 ($C_3H_2N_2Cl$) and 131.0008 ($C_4H_4N_2OCl$) were observed. The presence of the $-OH$ group on the other N of the imidazole group would not explain the easy loss of water observed in ESI+. Another possibility would be the hydroxyl group to be located in the benzylic carbon, although this would hamper (but not prevent) the formation of the ions 235/207 in ESI+.

After a literature search [29], three hydroxylated candidates were found (see the hydroxylated reported sites, marked as (•) in **Figure 5**): two metabolites are hydroxylated in the alkylic chain and the other in the benzylic carbon. However, on the basis of the MS/MS fragmentation, it was not possible to unequivocally locate the position of the $-OH$ group. It would be very interesting to perform NMR to help identify the structure of these compounds. However, this was not possible due to the expected low concentrations of the discovered TPs together with the need for on-line coupling of UHPLC separations to NMR spectroscopy. Unfortunately, this type of instrumentation is not easily available in our area.

It is interesting to remark that losartan, its carboxylic acid and the two hydroxylated metabolites were found in all water samples analysed (10 surface, 7 effluent WW, 7 influent WW).

Conclusions

The potential of UHPLC-QTOF MS for large screening of more than 1000 licit and illicit drugs, even without the need of having all reference standards available, has allowed the detection of many of these compounds in water samples from the area of Bogotá. The screening performed in urban wastewater and surface water confirmed the presence of emerging contaminants, mainly pharmaceuticals, in the samples. This work provides new information on the occurrence of these compounds and metabolites in the Colombian water cycle. The availability of full-spectrum acquisition accurate-mass QTOF data will also facilitate in the future, retrospective analysis of other contaminants not considered in this initial screening, if required. The results obtained in this first study may help Colombian institutions to select priority contaminants for future actions. Thus, target methodologies, typically based on LC-MS/MS, will need to be set up in the near future for accurate and sensitive quantification of the contaminants selected on the basis on the information provided in the present paper.

Acknowledgments

The authors are very grateful to Nubia Irley León and colleagues of Acueducto de Bogotá (Bogotá, Colombia) for providing wastewater samples, Natalia Gonzalez³ for preparing the wastewater samples, Jose Roberto Vergas² for collecting and processing the surface water samples, and Carlos Sales Martinez¹ for making figure 1. Furthermore, the collaboration of Juan V. Sancho¹ and Oscar J. Pozo of the Hospital del Mar Medical Research Institute, Bioanalysis Research Group (Barcelona, Spain), for the interpretation of the fragmentation pathways of the losartan metabolites is highly appreciated.

This work has been developed under financial support provided by the Plan Nacional de I+D+I, Ministerio de Economía y Competitividad (Project ref. CTQ2012-36189) and the University Antonio Nariño, Colombia (Project ref. 20141082). The authors also acknowledge the financial support from Generalitat Valenciana (Group of Excellence Prometeo 2009/054, Prometeo II 2014/023; Collaborative Research on Environment and Food Safety ISIC/2012/016).

R. Bade acknowledges the European Union for his Early Stage Researcher (ESR) contract as part of the EU-International Training Network SEWPROF (Marie Curie-PEOPLE Grant #317205).

Supplementary information

In this section, a table is shown of the human and veterinary pharmaceuticals including metabolites (**Table SI1**), X-Ray agents (**Table SI2**), UV-filters (**Table SI3**), preservatives (**Table SI4**), sweeteners (**Table SI5**) and illicit drugs including metabolites (**Table SI6**) studied.

References

1. Pal A, He Y, Jekel M, Reinhard M, Yew-Hoon Gin K (2014) Emerging contaminants of public health significance as water quality indicator compounds in the urban water cycle. *Environm Int* 71:46-62
2. Richardson SD, Ternes TA (2014) Water Analysis: Emerging Contaminants and Current Issues. *Anal Chem* 86:2813-2848
3. Fatta-Kassinos D, Meric S, Nikolaou A (2011) Pharmaceutical residues in environmental waters and wastewater: current state of knowledge and future research. *Anal Bioanal Chem* 399:251-275
4. Gros M, Petrovic M, Ginebreda A, Barceló D (2010) Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. *Environm Int* 36:15-26
5. Thomas KV, Araújo da Silva FM, Langford KH, Leão de Souza A, Nizzeto L, Waichman AV (2014) Screening for selected human pharmaceuticals and cocaine in the urban streams of Manaus, Amazonas, Brazil. *JAWRA* 50:302-308
6. De Paula VS, Diniz-Mendes L, Villar LM, Luz SLB, Silva LA, Jesus MS, da Silva NMVS, Gaspar AMC (2007) Hepatitis A virus in environmental water samples from the Amazon Basin. *Water Res* 41:1169-1176
7. Montagner CC, Jardim WF (2011) Spatial and seasonal variations of pharmaceuticals and endocrine disruptors in the Atibaia River, São Paulo State (Brazil). *J Braz Chem Soc* 22:1452-1462
8. Gracia-Lor E, Martínez M, Sancho JV, Peñuela G, Hernández F (2012) Multi-class determination of personal care products and pharmaceuticals in environmental and wastewater samples by ultra-high performance liquid-chromatography-tandem mass spectrometry. *Talanta* 99:1011-1023
9. Boxall ABA, Rudd MA, Brooks BW, Caldwell DJ, Choi K, Hickmann S, Innes E, Ostapyk K, Staveley JP, Verslycke T, Ankley GT, Beazley KF, Belanger SE, Berninger JP, Carriquiriborde P, Coors A, DeLeo PC, Dyer SD, Ericson JF, Gagné F, Giesy JP, Gouin T, Hallstrom L, Karlsson MV, Larsson DGJ, Lazorchak JM, Mastrocco F, McLaughlin A, McMaster ME, Meyerhoff RD, Moore R, Parrott JL, Snape JR, Murray-Smith R, Servos MR, Sibley PK, Straub JO, Szabo ND, Topp E, Tetreault GR, Trudeau VL, van der Kraak G (2012) Pharmaceuticals and Personal

- Care Products in the Environment: What Are the Big Questions? *Environ Health Perspect* 120:1221-1229
10. Schymanski EL, Singer HP, Longrée P, Loos M, Ruff M, Stravs MA, Ripollés Vidal C, Hollender J (2014) Strategies to Characterize Polar Organic Contamination in Wastewater: Exploring the Capability of High Resolution Mass Spectrometry. *Environ Sci Technol* 48:1811-1818
 11. Hernández F, Ibáñez M, Bade R, Bijlsma L, Sancho JV (2014) Investigation of pharmaceuticals and illicit drugs in waters by liquid chromatography-high-resolution mass spectrometry. *Trends Anal Chem* 63:140-157
 12. Díaz R, Ibáñez M, Sancho JV, Hernández F (2012) Target and non-target screening strategies for organic contaminants, residues and illicit substances in food, environmental and human biological samples by UHPLC-QTOF-MS. *Anal Meth* 4:196-209
 13. Hernández F, Bijlsma L, Sancho JV, Díaz R, Ibáñez M (2011) Rapid wide-scope screening of drugs of abuse, prescription drugs with potential for abuse and their metabolites in influent and effluent urban wastewater by ultrahigh pressure liquid chromatography–quadrupole-time-of-flight-mass spectrometry. *Anal Chim Acta* 684: 96-106
 14. Laks S, Pelander A, Vuori E, Ali-Toppa E, Sippola E, Ojanpera I (2004) Analysis of street drugs in seized material without primary reference standards. *Anal Chem* 76: 7375-7379
 15. Hernández F, Portolés T, Ibáñez M, Bustos-López MC, Díaz R, Botero-Coy AM, Fuentes CL, Peñuela G (2012) Use of time-of-flight mass spectrometry for large screening of organic pollutants in surface waters and soils from a rice production area in Colombia. *Sci Total Environ* 439: 249-259
 16. MassBank Norman. High Resolution Mass Spectral Database. <http://massbank.ufz.de/MassBank/> Accessed 29 Jan 2015
 17. Metlin. Metabolite and tandem MS database. <http://metlin.scripps.edu/index.php> Accessed 29 Jan 2015
 18. Schymanski EL, Jeon J, Gulde R, Fenner K, Ruff M, Singer HP, Hollender J (2014) Identifying Small Molecules via High Resolution Mass Spectrometry: Communicating Confidence. *Environ Sci Technol* 48:2097-2098

19. Hernández F, Ibáñez M, Gracia-Lor E, Sancho JV (2011) Retrospective LC–QTOF-MS analysis searching for pharmaceutical metabolites in urban wastewater. *J Sep Sci* 34:3517–3526
20. López JJ, Dennis R, Moscoso SM (2009) Estudio sobre la Automedicación en una localidad de Bogotá. *Revista de Salud Pública* 11:432-442
21. Rodríguez J, Ruiz F, Peñaloza E, Eslava J, Gómez LC, Sanchez H, Amaya JL, Arenas R, Botiva Y. (2009) Encuesta Nacional de Salud 2007. ISBN 978-958-716-220-2
22. Machado-Alba JE, González-Santos DM (2009) Dispensación de antibióticos de uso ambulatorio en una población colombiana. *Revista de Salud Pública* 11:734-744
23. United Nations Office on Drugs and Crime. https://www.unodc.org/documents/colombia/2014/Julio/Estudio_de_Consumo_UN_ODC.pdf Accessed 26 Jan 2015
24. Bijlsma L, Beltrán E, Boix C, Sancho JV, Hernández F (2014) Improvements in analytical methodology for the determination of frequently consumed illicit drugs in urban wastewater. *Anal Bioanal Chem* 406:4261 – 4272
25. Ort C, van Nuijs ALN, Berset J-D, Bijlsma L, Castiglioni S, Covaci A, de Voogt P, Emke E, Fatta-Kassinos D, Griffiths P, Hernández F, González-Mariño I, Grabic R, Kasprzyk-Hordern B, Mastroianni N, Meierjohann A, Nefau T, Östman M, Pico Y, Racamonde I, Reid M, Slobodnik J, Terzic S, Thomaidis N, Thomas KV (2014) Spatial differences and temporal changes in illicit drug use in Europe quantified by wastewater analysis. *Addiction*, 109;1338-1352
26. Pedrouzo M, Borrull F, Pocurull E, Marcé RM (2011) Drugs of abuse and their metabolites in waste and surface waters by Liquid Chromatography-tandem Mass Spectrometry. *J Sep Sci* 34:1091–1101
27. Ibáñez M, Pozo OJ, Sancho JV, Orengo T, Haro G, Hernández F (2015) Discovering human urinary metabolites of methylenedioxypropylamphetamine (MDPV) by Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry. *Forensic Toxicol* submitted
28. Bijlsma L, Boix C, Niesen WMA, Ibáñez M, Sancho JV, Hernández F (2013) Investigation of degradation products of cocaine and benzoylecgonine in the aquatic environment. *Sci Total Environ* 443:200-208

29. PGKB Pharmacogenomics. <https://www.pharmgkb.org/pathway/PA164713428#>
Accessed 29 Jan 2015

Table 1. Positive findings by UHPLC-(Q)TOF MS in 10 surface water samples. Results obtained in influent and effluent samples.

COMPOUND	SURFACE WATER (number of the sampling site)										INFLUENT* (n=7)	EFFLUENT* (n=7)	
	1	2	3	4	5	6	7	8	9	10			
<i>Pharmaceuticals and veterinary drugs</i>													
4-Acetamido antipyrine	√	√	√	√	√	√	√	√	√	√	√	√	√
4-Formylamino antipyrine		√	√	√	√	√	√	√	√	√	√	√	√
Acetaminophen/paracetamol	√			√		√	√		√	√	√	√	√
Carbamazepine	√	√	√	√	√	√	√	√	√	√	√	√	√
Carbamazepine 10,11-dihydro- 10,11-dihydroxy	√	√	√	√	√	√	√	√	√	√	√	√	√
Clarithromycin		√	√					√	√	√	√	√	√
Clindamycin						√			√	√			
Codeine				•									•
Diclofenac		√	√	√							√	√	√
Dimetridazole		√	√										
Gabapentin													•
Gemfibrozil	√	√	√	√		√	√	√	√	√	√		
Ibuprofen		√		√				√			√	√	√
Iopromide				√									√
Irbesartan											√	√	√
Ketoprofen				√							√	√	√
Levamisole			√	√									√
Lidocaine**	⊕ √	⊕ √	⊕ √	⊕ √		⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √
Lincomycin		√	√	√		√	√	√	√	√			√
Losartan	√	√	√	√	√	√	√	√	√	√	√	√	√
Losartan, carboxylic acid**	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √	⊕ √

Losartan, hydroxy (1)	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕
Losartan, hydroxy (2)	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕
Metformin		⊕	⊕	⊕							⊕	⊕
Metoprolol		•	•	•		•		•	•	•	•	•
Metronidazole	√	√	√	√								
Naproxen	√	√	√	√							√	√
Pirantel			⊕	⊕								
Salbutamol				√								
Sulfamethoxazole		√	√	√							√	√
Trimethoprim		√	√	√							√	√
Valsartan		√	√	√		√	√	√	√	√	√	√
<i>Psychoactive drugs</i>												
Benzoylcegonine	√	√	√	√		√	√	√	√	√	√	√
Caffeine	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕
Cocaine	√	√	√	√		√		√	√	√		√
<i>Preservatives</i>												
Methylparaben												√
Propylparaben											√	√
<i>Sweeteners</i>												
Acesulfame		•	•	•	•	•	√	•	•	√	√	√
Saccharin	⊕			⊕	⊕	⊕	⊕	⊕	⊕		⊕	⊕
Sucralose	•	•	•	√	•	•	√	√	√	√	√	√

(•) Detected, not confirmed (1 accurate-mass ion <5 ppm + retention time <2.5%).

(√) Confirmed with at least two accurate-mass ions (<5ppm) and retention time (<2.5%) with reference standard.

(⊕) Tentatively identified (at least two accurate-mass ions justified by literature data and/or compatible with the candidate chemical structure).

*Results given for IWW and EWW correspond to seven samples (one whole week). The compounds indicated as ●, ⊕ or √ were found in at least 6 out of 7 samples analysed.

**These compounds were firstly tentatively identified in the samples and afterwards confirmed with reference standards.

Figure captions

Figure 1. Location of sampling sites


Figure 2. Detection and identification of metabolite 4-acetylamino antipyrine in surface water by UHPLC-QTOF MS. (a) Low energy (LE, bottom) and high energy (HE, top) mass spectra for the peak at 3.78 min; (b) eXtracted Ion Chromatograms (XICs) at 150 ppm mass window for $[M+H]^+$ in LE, and main fragments in HE.

Figure 3. Tentative identification of lidocaine and caffeine in effluent wastewater by UHPLC-QTOF MS. (a) LE and HE mass spectra for the peaks at 3.89 and 3.98 min in positive ionization mode; (b) XICs at 150 ppm mass window for $[M+H]^+$ of lidocaine (3.98 min) and caffeine (3.89 min) in LE, and for the fragment ions (m/z 86, 138 and 110) in HE.

Figure 4. Common fragmentation pathway strategy applied for the detection of metabolites of losartan. (a) eXtracted Ion Chromatograms (XICs) at 150 ppm mass window for $[M+H]^+$ of losartan in LE function, and (b) main fragments (m/z 207, 235, 190) in HE function; (c) XICs at 150 ppm mass window for $[M+H]^+$ of possible carboxylic acid metabolite in LE function; (d) XICs at 150 ppm mass window for $[M+H]^+$ of possible hydroxylated metabolites of losartan in LE function.

Figure 5. MS/MS spectra at 10 eV (bottom), 20 eV (middle) and 50 eV (top) for hydroxylated metabolite 1 (8.25 min) in (a) ESI⁺ and (b) ESI⁻


(●) indicates the possible hydroxylation sites, as reported in the literature.




Sampling points

Number	Name/Description
1	Landfill, Doña Juana (Tunjuelo river)
2	San Benito (tanneries area) (Tunjuelo river)
3	Guadalupe (slaughterhouse) (Tunjuelo river)
4	Bosa (Tunjuelo river)
5	Irrigation channel San Jose- La Victoria (Ramada irrigation area)
6	Irrigation channel San Jose- Los Pinos (Ramada irrigation area)
7	Wetland Güali-Tres Esquinas (Ramada irrigation area)
8	Canal C. Agricultural Center, Marengo (Ramada irrigation area)
9	Canal C. Agricultural Center, Marengo (Ramada irrigation area)
10	Exit of swamp (Ramada irrigation area)
11	Wastewater, Salitre WWTP Seven influent and seven effluent wastewater samples (one whole week)

Figure 1.




(b)




(a)

Figure 2.



(b)



(a)




Figure 3






Figure 4




Figure 5